Provention Bio Inc Equity-NMS: PRVB

Healthcare

Biotechnology

Buy/Sell an entire stock
or a fraction.

Vested

Already an existing customer?

New User?

Open Your Free Demat Account And Start Trading Seamlessly

Loading, Please wait...

Error in Fetching Data, Please retry later.

No data available.

Previous close :

$9.3

52W high :

$9.85

1Y :

11.62%

5Y :

-9.38%

Shares O/S :

87.19 M

Market cap :

820.46 M

What is the share price of Provention Bio Inc today?

Provention Bio Inc (PRVB) share price as of October 12, 2022, is $7.07. If you are investing from India, you can always check the valuation in the INR before investing.

Can Indian Investors purchase shares of Provention Bio Inc?

Yes, Indian Investors can invest in the Provention Bio Inc (PRVB) Share by opening an international trading account with Angel One.

How can I purchase Provention Bio Inc shares in India?

Purchasing Provention Bio Inc (PRVB) share from India can be done by:

Directly: By opening an international trading account with Angel One. The process would include KYC verification.
The account activation takes a few minutes to a few hours, after which you can start buying Provention Bio Inc (PRVB) by making deposits in US dollars.
Indirectly: By investing in mutual funds and Exchange Traded Funds (ETF) that offers exposure in global stocks.

Can I buy Fractional shares of Provention Bio Inc?

Yes, you can purchase fractional shares of Provention Bio Inc (PRVB) or any other US company shares in Angel One for any dollar amount.

What is the market capitalization value of Provention Bio Inc?

The market capitalization of Provention Bio Inc on December 3, 2022, is $576.56 M.

In which sector Provention Bio Inc belongs?

Provention Bio Inc operates in the Healthcare sector, specifically in the Biotechnology industry.

What documents are required to invest in Provention Bio Inc stocks?

In order to invest in Provention Bio Inc (PRVB) you will need Proof of Identification (Aadhaar, PAN, Passport etc.) and Proof of Address (Aadhaar, Voter Card etc.)

From start to end, the process is digital and can be seamless.

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that focuses on intercepting and preventing immune-mediated diseases. The Company's product pipeline includes PRV-031 (teplizumab), PRV-3279, PRV-015 (ordesekimab) and PRV-101. Teplizumab is a humanized, anti-CD3 monoclonal antibody (mAb) for the delay of clinical type 1 diabetes (T1D) in at-risk individuals and for patients with newly diagnosed T1D. PRV-3279 is a humanized bispecific scaffold molecule targeting the B-cell surface proteins, CD32B and CD79B, for the treatment of systemic lupus erythematosus (SLE) and for the prevention of immunogenicity of biotherapeutics, such as those used in gene therapy. Ordesekimab is a human anti-interleukin 15 (IL-15) mAb for the treatment of gluten-free diet non-responsive celiac disease (NRCD). PRV-101 is a coxsackievirus B (CVB) vaccine to prevent acute CVB infections and, in those patients at-risk, to prevent the CVB-triggered autoimmune damage to pancreatic beta-cells.